卵巢癌标志物CA125酶联免疫吸附分析法的建立  

Measurement of CA125 in serum by an enzymelinked immunosorbent assay

作　　者：黄文林[1] 王雯[1] 王晓静[1] 崔素珍[1] 马京民 王玉肖[1] 

机构地区：[1]中国原子能科学研究院同位素研究所

出　　处：《中国免疫学杂志》1999年第6期273-275,共3页Chinese Journal of Immunology

摘　　要：目的：建立一种血清ＣＡ１２５的临床检测方法。方法：一株ＣＡ１２５单抗用于固相包被，另一株与辣根过氧化物酶偶联制备ＣＡ１２５的酶标记物，以四甲基联苯胺（ＴＭＢ）为底物，采用一步法，建立了ＣＡ１２５的酶联免疫吸附分析法（ＥＬＩＳＡ）。结果：灵敏度为２００Ｕ／ｍｌ。批内ＣＶ值低于５．３２％（ｎ＝２２），批间ＣＶ值低于７．３９％（ｎ＝２６）。测得回收率均值为１００．９％，６０例正常人血清的均值为９．２０Ｕ／ｍｌ，应用本法与ＩＲＭＡ方法同时测定３３例病人血样，两者相关方程为Ｙ＝０．８２５Ｘ－１０．３９，相关系数ｒ＝０．９６００。结论：该方法具有简便、快速和准确的特点，未见“ＨＯＯＫ”效应的影响，适于临床检测和科研应用。Objective: To develop a clinical method to measure ovarian cancer marker CA125 in serum. Methods:ZThe onestep assay is based on enzymelinked immunosorbent assay (ELISA). One monoclonal antibody is employed for coating, another for labeling with horseradish peroxidase. Results: The minimum detectable dose is 2.00 U/ml and analytical recovery of CA125 is 91.1% to 107.4%. The betweenruns CVs and the withinruns CVs of 3 samples are lower than 7.39% and 5.32% respectively. The average concentration of CA125 in sera from 60 healthy women is 9.20 U/ml. The correlation of results with CA125 IRMA is 0.960 0. Conclusion: The assay is a rapid, sensitive and precise method and simple to perform. It is suitable for clinical and research application.

关 键 词：CA125 酶联免疫分析法 卵巢癌 

分 类 号：R737.310.3[医药卫生—肿瘤]